The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+


Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

What is Neuromodulation?

Breaking News Share

Deal Calls for Modified Vagus Nerve Stimulation System for Preclinical Research

July 26, 2017 - EnteroMedics, Inc. entered a collaboration agreement with Galvani Bioelectronics Limited to modify its vagus nerve stimulation implant for use in preclinical research by Galvani. In the agreement, EnteroMedics will receive development payments and retain rights to the new device, licensing it to Galvani. The abdominal implant was FDA approved in 2015 for addressing obesity by limiting feelings of hunger. (Fierce Biotech)

Data Show Increased Adoption of Sacral Neuromodulation for Overactive Bladder

June 27, 2017 - Case logs from the American Board of Urology show that from 2003 to 2012, the number of sacral neuromodulation procedures for overactive bladder increased from 48 to 2068. By contrast, the number of augmentation cystoplasty procedures remained stable, with 14 to 38 cases reported annually. Proportionally, the augmentation procedure dropped from 25% to less than 1% of cases. (Female Pelvic Medicine & Reconstructive Surgery)

Company Launches U.S. Sales and Registry of Non-invasive Vagus Nerve Stimulator for Episodic Cluster Headache

July 18, 2017 - A hand-held vagus nerve stimulation device is being launched in the U.S. for acute treatment of pain from episodic cluster headaches in adults by the device company electroCore, following FDA approval in April. The company is also launching a device registry to gather patient experience and self-reported quality-of-life information. (PR Newswire)


To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM